Lapaquistat is a cholesterol-lowering drug candidate within the squalene synthase inhibitor class, originally developed to modulate the cholesterol biosynthesis pathway. Although the compound was discontinued… Read more
Lapaquistat is a cholesterol-lowering drug candidate within the squalene synthase inhibitor class, originally developed to modulate the cholesterol biosynthesis pathway. Although the compound was discontinued during clinical development and never reached the commercial market, it remains a subject of research in pharmacological studies. Laboratories utilize this category of reference standards to support analytical method development and quality control processes. This collection includes high-purity Lapaquistat API and related compounds, such as stable isotope labelled internal standards like Lapaquistat-d9 acetate. These materials are essential for impurity profiling, allowing researchers to accurately identify and quantify degradants or synthesis by-products during stability testing. By employing these reference materials in mass spectrometry and other analytical techniques, scientists can ensure rigorous characterization and validation of experimental procedures involving this benzoxazepine derivative.